Providing Biological Plausibility for Exposure-Health
Relationships for the Mycotoxins Deoxynivalenol (DON) and
Fumonisin B1 (FB1) in Humans Using the AOP Framework

J 2022

Providing Biological Plausibility for Exposure-Health Relationships for the Mycotoxins Deoxynivalenol (DON) and Fumonisin B1 (FB1) in Humans Using the AOP Framework

VAN DEN BRAND, Annick D.; Lola Murielle BAJARD ÉP.ESNER; Inger-Lise STEFFENSEN; Anne Lise BRANTSAETER; Hubert A. A. M. DIRVEN et al.

Základní údaje

Originální název

Providing Biological Plausibility for Exposure-Health Relationships for the Mycotoxins Deoxynivalenol (DON) and Fumonisin B1 (FB1) in Humans Using the AOP Framework

Autoři

Vydání

Toxins, MDPI, 2022, 2072-6651

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30108 Toxicology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.200

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/22:00126022

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

AOP; adverse outcome pathway; HBM; human biomonitoring; HBM4EU; human biomonitoring for Europe; DON; deoxynivalenol; FB1; fumonisin B1; mycotoxins

Štítky

143180, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 6. 2025 11:36, Mgr. Michaela Hylsová, Ph.D.

Anotace

V originále

Humans are chronically exposed to the mycotoxins deoxynivalenol (DON) and fumonisin B1 (FB1), as indicated by their widespread presence in foods and occasional exposure in the workplace. This exposure is confirmed by human biomonitoring (HBM) studies on (metabolites of) these mycotoxins in human matrices. We evaluated the exposure-health relationship of the mycotoxins in humans by reviewing the available literature. Since human studies did not allow the identification of unequivocal chronic health effects upon exposure to DON and FB1, the adverse outcome pathway (AOP) framework was used to structure additional mechanistic evidence from in vitro and animal studies on the identified adverse effects. In addition to a preliminary AOP for DON resulting in the adverse outcome (AO) 'reduced body weight gain', we developed a more elaborated AOP for FB1, from the molecular initiating event (MIE) 'inhibition of ceramide synthases' leading to the AO 'neural tube defects'. The mechanistic evidence from AOPs can be used to support the limited evidence from human studies, to focus FB1- and DON-related research in humans to identify related early biomarkers of effect. In order to establish additional human exposure-health relationships in the future, recommendations are given to maximize the information that can be obtained from HBM.

Návaznosti

EF17_043/0009632, projekt VaV

Název: CETOCOEN Excellence

733032, interní kód MU

Název: European Human Biomonitoring Initiative (Akronym: HBM4EU)

Investor: Evropská unie, European Human Biomonitoring Initiative, Health, demographic change and wellbeing (Societal Challenges)

857560, interní kód MU
(Kód CEP: EF17_043/0009632)

Název: CETOCOEN Excellence (Akronym: CETOCOEN Excellence)

Investor: Evropská unie, CETOCOEN Excellence, Spreading excellence and widening participation

90121, velká výzkumná infrastruktura

Název: RECETOX RI

Přiložené soubory

1860504.pdf

Citovat

VAN DEN BRAND, Annick D.; Lola Murielle BAJARD ÉP.ESNER; Inger-Lise STEFFENSEN; Anne Lise BRANTSAETER; Hubert A. A. M. DIRVEN; Jochem LOUISSE; Ad PEIJNENBURG; Sophie NDAW; Alberto MANTOVANI; Barbara DE SANTIS a Marcel J. B. MENGELERS. Providing Biological Plausibility for Exposure-Health Relationships for the Mycotoxins Deoxynivalenol (DON) and Fumonisin B1 (FB1) in Humans Using the AOP Framework. Toxins. MDPI, 2022, roč. 14, č. 4, s. 1-21. ISSN 2072-6651. Dostupné z: https://doi.org/10.3390/toxins14040279.

@article{1860504,
   author = {van den Brand, Annick D. and Bajard ép.Esner, Lola Murielle and Steffensen, IngerandLise and Brantsaeter, Anne Lise and Dirven, Hubert A. A. M. and Louisse, Jochem and Peijnenburg, Ad and Ndaw, Sophie and Mantovani, Alberto and De Santis, Barbara and Mengelers, Marcel J. B.},
   article_number = {4},
   doi = {https://doi.org/10.3390/toxins14040279},
   keywords = {AOP; adverse outcome pathway; HBM; human biomonitoring; HBM4EU; human biomonitoring for Europe; DON; deoxynivalenol; FB1; fumonisin B1; mycotoxins},
   language = {eng},
   issn = {2072-6651},
   journal = {Toxins},
   title = {Providing Biological Plausibility for Exposure-Health Relationships for the Mycotoxins Deoxynivalenol (DON) and Fumonisin B1 (FB1) in Humans Using the AOP Framework},
   url = {https://www.mdpi.com/2072-6651/14/4/279},
   volume = {14},
   year = {2022}
}

TY  - JOUR
ID  - 1860504
AU  - van den Brand, Annick D. - Bajard ép.Esner, Lola Murielle - Steffensen, Inger-Lise - Brantsaeter, Anne Lise - Dirven, Hubert A. A. M. - Louisse, Jochem - Peijnenburg, Ad - Ndaw, Sophie - Mantovani, Alberto - De Santis, Barbara - Mengelers, Marcel J. B.
PY  - 2022
TI  - Providing Biological Plausibility for Exposure-Health Relationships for the Mycotoxins Deoxynivalenol (DON) and Fumonisin B1 (FB1) in Humans Using the AOP Framework
JF  - Toxins
VL  - 14
IS  - 4
SP  - 1-21
EP  - 1-21
PB  - MDPI
SN  - 20726651
KW  - AOP
KW  - adverse outcome pathway
KW  - HBM
KW  - human biomonitoring
KW  - HBM4EU
KW  - human biomonitoring for Europe
KW  - DON
KW  - deoxynivalenol
KW  - FB1
KW  - fumonisin B1
KW  - mycotoxins
UR  - https://www.mdpi.com/2072-6651/14/4/279
N2  - Humans are chronically exposed to the mycotoxins deoxynivalenol (DON) and fumonisin B1 (FB1), as indicated by their widespread presence in foods and occasional exposure in the workplace. This exposure is confirmed by human biomonitoring (HBM) studies on (metabolites of) these mycotoxins in human matrices. We evaluated the exposure-health relationship of the mycotoxins in humans by reviewing the available literature. Since human studies did not allow the identification of unequivocal chronic health effects upon exposure to DON and FB1, the adverse outcome pathway (AOP) framework was used to structure additional mechanistic evidence from in vitro and animal studies on the identified adverse effects. In addition to a preliminary AOP for DON resulting in the adverse outcome (AO) 'reduced body weight gain', we developed a more elaborated AOP for FB1, from the molecular initiating event (MIE) 'inhibition of ceramide synthases' leading to the AO 'neural tube defects'. The mechanistic evidence from AOPs can be used to support the limited evidence from human studies, to focus FB1- and DON-related research in humans to identify related early biomarkers of effect. In order to establish additional human exposure-health relationships in the future, recommendations are given to maximize the information that can be obtained from HBM.
ER  -

VAN DEN BRAND, Annick D.; Lola Murielle BAJARD ÉP.ESNER; Inger-Lise STEFFENSEN; Anne Lise BRANTSAETER; Hubert A. A. M. DIRVEN; Jochem LOUISSE; Ad PEIJNENBURG; Sophie NDAW; Alberto MANTOVANI; Barbara DE SANTIS a Marcel J. B. MENGELERS. Providing Biological Plausibility for Exposure-Health Relationships for the Mycotoxins Deoxynivalenol (DON) and Fumonisin B1 (FB1) in Humans Using the AOP Framework. \textit{Toxins}. MDPI, 2022, roč.~14, č.~4, s.~1-21. ISSN~2072-6651. Dostupné z: https://doi.org/10.3390/toxins14040279.

Přehled o publikaci